The amino acid substitution Q65H in the 2C protein of swine vesicular disease virus confers resistance to golgi disrupting drugs by Vázquez-Calvo, Ángela et al.
ORIGINAL RESEARCH
published: 27 April 2016
doi: 10.3389/fmicb.2016.00612
Frontiers in Microbiology | www.frontiersin.org 1 April 2016 | Volume 7 | Article 612
Edited by:
José A. Melero,
Instituto de Salud Carlos III, Spain
Reviewed by:
Carolyn Machamer,
Johns Hopkins School of Medicine,
USA
Martin J. Richer,
McGill University, Canada
*Correspondence:
Francisco Sobrino
fsobrino@cbm.csic.es;
Miguel A. Martín-Acebes
martin.mangel@inia.es
Specialty section:
This article was submitted to
Virology,
a section of the journal
Frontiers in Microbiology
Received: 16 February 2016
Accepted: 13 April 2016
Published: 27 April 2016
Citation:
Vázquez-Calvo Á, Caridi F,
González-Magaldi M, Saiz J-C,
Sobrino F and Martín-Acebes MA
(2016) The Amino Acid Substitution
Q65H in the 2C Protein of Swine
Vesicular Disease Virus Confers
Resistance to Golgi Disrupting Drugs.
Front. Microbiol. 7:612.
doi: 10.3389/fmicb.2016.00612
The Amino Acid Substitution Q65H in
the 2C Protein of Swine Vesicular
Disease Virus Confers Resistance to
Golgi Disrupting Drugs
Ángela Vázquez-Calvo 1, 2, Flavia Caridi 1, Mónica González-Magaldi 1, Juan-Carlos Saiz 2,
Francisco Sobrino 1* and Miguel A. Martín-Acebes 1, 2*
1Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain, 2Departamento de Biotecnología, Instituto
Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain
Swine vesicular disease virus (SVDV) is a porcine pathogen and a member of the species
Enterovirus B within the Picornaviridae family. Brefeldin A (BFA) is an inhibitor of guanine
nucleotide exchange factors of Arf proteins that induces Golgi complex disassembly
and alters the cellular secretory pathway. Since BFA has been shown to inhibit the RNA
replication of different enteroviruses, including SVDV, we have analyzed the effect of BFA
and of golgicide A (GCA), another Golgi disrupting drug, on SVDV multiplication. BFA
and GCA similarly inhibited SVDV production. To investigate the molecular basis of the
antiviral effect of BFA, SVDV mutants with increased resistance to BFA were isolated. A
single amino acid substitution, Q65H, in the non-structural protein 2C was found to be
responsible for increased resistance to BFA. These results provide new insight into the
relationship of enteroviruses with the components of the secretory pathway and on the
role of SVDV 2C protein in this process.
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INTRODUCTION
Swine vesicular disease virus (SVDV) is a member of the species Enterovirus B within the
Picornaviridae family. SVDV is the etiological agent of a highly contagious disease of pigs (SVD)
and is closely related to the human pathogen coxsackievirus B5, CVB5 (Zhang et al., 1999; Bruhn
et al., 2015). As other RNA viruses, enterovirus populations are quasispecies and exhibit a high
potential for variation and adaptation, including the rapid selection of drug resistant variants
(Andino and Domingo, 2015).
SVDV genome is composed of a single-stranded RNA molecule of positive polarity that is
translated using an internal ribosome entry site (IRES) to produce a single polyprotein that is
processed into the mature viral proteins (Zhang et al., 1993; Escribano-Romero et al., 2000). The
four structural proteins (VP1-VP4) form an icosahedral capsid of approximately 25–30 nm in
diameter and the seven non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D) are involved
in the virus life cycle (Whitton et al., 2005; Buenz and Howe, 2006). Positive-strand RNA viruses
induce a dramatic remodeling of the intracellular membranes of infected cells aimed to develop
an adequate environment for RNA replication (Hsu et al., 2010; Harak and Lohmann, 2015). In
fact, these structures are considered specialized organelles for viral replication (Hsu et al., 2010;
Richards et al., 2014). In enteroviruses, such as SVDV, RNA replication takes place at the surface of
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cytoplasmic vesicular structures derived from cellular
membranes of the endoplasmic reticulum (ER) and the
Golgi complex (Martín-Acebes et al., 2008; Belov and Sztul, 2014;
Linden et al., 2015). Studies mostly performed with poliovirus
(PV) have shown that the enteroviral proteins 2B, 2C, and
3A are involved on membrane rearrangements (Bienz et al.,
1994; Suhy et al., 2000; Belov et al., 2008; Hsu et al., 2010),
albeit the mechanisms of membrane reorganization are not
well understood yet. In some cases, the proposed mechanism of
action of these non-structural proteins involves their interaction
with host cell proteins from the secretory pathway, which can
vary among picornaviruses (Gazina et al., 2002; Martín-Acebes
et al., 2008; van der Linden et al., 2010; Sasaki et al., 2012).
Brefeldin A (BFA) is a fungal metabolite that inhibits the
replication of several enteroviruses, including PV and SVDV
(Maynell et al., 1992; Crotty et al., 2004; Martín-Acebes et al.,
2008; van der Linden et al., 2010; Viktorova et al., 2015). BFA
blocks the function of the cellular protein ADP ribosylation factor
1 (Arf1) through the inhibition of several guanine nucleotide
exchange factors (GEFs) that regulate its activity, such as GBF1
(Golgi-specific BFA resistance factor 1), BIG1 (BFA-inhibited
GEF 1) and BIG2 (Klausner et al., 1992; Chardin andMcCormick,
1999). Arf1 is localized on the Golgi complex and the ER-Golgi
intermediate compartment. Its activated form induces formation
of secretory vesicles via recruitment of effector proteins such
as the coatomer protein complex I (COP-I) during vesicle
budding (D’Souza-Schorey and Chavrier, 2006; Donaldson and
Jackson, 2011). Golgicide A (GCA) is also an inhibitor of GBF1
(Pan et al., 2008; Sáenz et al., 2009). Despite BFA and GCA
induce fragmentation of the Golgi complex by inhibition of Arf1
activation, they can differentially affect picornavirus replication
(Martín-Acebes et al., 2008; van der Linden et al., 2010). The
differences in the sensitivity to Golgi disrupting drugs support
that diverse cellular factors are required among picornaviruses
to form the replication complex. Thus, BFA and GCA have
become useful tools to analyze the requirements for picornavirus
replication (Gazina et al., 2002; Martín-Acebes et al., 2008; van
der Linden et al., 2010; Mousnier et al., 2014). In this context,
PV variants resistant to BFA show point mutations associated to
resistance that are located in the 2C and 3A proteins (Crotty et al.,
2004; Viktorova et al., 2015).
In this study, we show that BFA and GCA inhibit SVDV
replication. Furthermore, the analysis of BFA-resistant SVDV
mutants revealed that a single amino acid substitution in 2C
protein was responsible for the increased resistance to BFA. These
results provide new insight into the relationship of enteroviruses
with the components of the secretory pathway and on the role of
SVDV 2C protein in these processes.
MATERIALS AND METHODS
Cells, Viruses, Reagents, and Antibodies
IBRS-2 (De Castro, 1964) and BHK-21 cells (ATCC) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco) supplemented with 5% fetal calf serum (FCS) (Gibco),
L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin
(100 µg/ml). The SVDV isolate used in this study, SPA/1/′93
(Jiménez-Clavero et al., 1998), was propagated on IBRS-2 cells.
Viral stocks of type C foot-and-mouth disease virus (FMDV)
C-S8c1 (Sobrino et al., 1983) and vesicular stomatitis virus
(VSV) Indiana (Vázquez-Calvo et al., 2011) were prepared by
amplification in BHK-21 cells. BFA and GCA (Sigma) were
dissolved in dimethyl sulfoxide (DMSO). Control cells were
treated in parallel with the same amount of drug vehicle. A rabbit
polyclonal antiserum against CVB3 2C protein was utilized for
SVDV protein detection (Martín-Acebes et al., 2008). Cis-Golgi
FIGURE 1 | Effect of Golgi disrupting drugs on SVDV, FMDV, and VSV
multiplication. (A) Effect of BFA (1, 2, 4, 6, 8, or 10 µg/ml) and GCA (1, 2, 4,
6, 8, or 10 µM) on IBRS-2 cell viability determined by ATP measurement. (B)
IBRS-2 cells were treated with DMSO (control), BFA (5 µg/ml) or GCA (10 µM)
for 30 min. Cells were fixed and processed for immunofluorescence using a
MAb against the cis-Golgi. Nuclei were stained using DAPI. Bar: 20 µm. (C)
IBRS-2 cells treated as in (B) were infected with the corresponding virus (moi
of 0.5 pfu/cell) in presence of the drug. At 8 h pi the viral titer was determined
by plaque assay. Error bars represent SD. The data presented correspond to
three independent experiments. Data were analyzed using ANOVA. Asterisk (*)
denote statistically significant differences with P < 0.05.
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networks was stained using MAb 25H8 to gp74 (Alcalde et al.,
1994) or a MAb to the C-terminal region of GM130 (ECM
Biosciences). Doubled-stranded RNA (dsRNA) was detected
using a MAb J2 (English & Scientific Consulting). Alexa Fluor
488 (green) and 594 (red) conjugated anti-mouse or anti-
rabbit secondary antibodies (Invitrogen) were used to recognize
primary antibodies in immunofluorescence assays.
Cell Viability Assay
The cytotoxicity of the drugs was determined by measuring the
cellular ATP using the CellTiter-Glo Luminiscent Cell Viability
assay (Promega). IBRS-2 cells were seeded in 96-well plates,
incubated with increasing concentrations of the drugs for 24 h,
and assayed as recommended by the manufacturer.
Immunofluorescence
Cells grown on glass coverslips were washed with PBS, fixed
with 4% paraformaldehyde or with methanol for gp74 staining,
blocked, and permeabilized with PBTG buffer (0.1% Triton
X-100, 1% bovine serum albumin [BSA], and 1M glycine in
PBS) for 15 min at room temperature. Samples were incubated
with primary antibodies diluted in 1% BSA in PBS for 1 h
at room temperature, washed with PBS, and incubated with
fluorescently labeled secondary antibodies for 30 min at room
temperature, as described (García-Briones et al., 2006). After
washing with PBS, nuclei were stained with 1 µg of DAPI
(4′,6′-diamidino-2-phenylindole; Invitrogen)/ml or with To-Pro-
3 (Molecular Probes). Samples were mounted in Fluoromount G
(Southern Biotech) and observed with an Axioskop microscope
(Zeiss) coupled to a digital monochrome camera coolsnap FX
(Roper Scientific). Images were acquired by using RS Image
1.9.2 software (Roper Scientific) and processed using Adobe
Photoshop CS2 (Adobe Systems, Inc.). For confocal laser
scanning microscopy, samples were observed using a Leica TCS
SPE confocal lases scanning microscope. Images were acquired
using Leica Advanced Fluorescence Software and processed
with Adobe Photoshop CS2 (Adobe Systems, Inc.). Optical slice
thickness for all confocal images displayed was of 1 airy unit.
Infections and Virus Titrations
Triplicate wells of IBRS-2 cells pretreated or not with the drugs
for 30 min were infected with VSV, SVDV, or FMDV using
a multiplicity of infection (moi) of 0.5 plaque forming units
(pfu)/cell. After the first infection hour, viral inoculum was
removed and fresh medium containing or not the drug and 5%
FCS was added (this time point was considered 1 h postinfection
[pi]). Eight hours later, cells were subjected to three freeze-
thaw cycles, and the total (intracellular and medium-released)
virus yield was determined by plaque assay (in BHK-21 cells
for VSV and FMDV or in IBRS-2 cells for SVDV), as described
(Martín-Acebes et al., 2009).
Isolation of BFA-Resistant SVDV Mutants
IBRS-2 cells were infected with SVDV in the presence of 0.5
µg/ml BFA and when total cytopathic effect was observed, cells
were subjected to three freeze-thaw cycles to harvest the progeny
virus (termed B1 population) and virus yield was determined
by plaque assay. This procedure of infection was repeated five
FIGURE 2 | BFA inhibits SVDV production in a dose-dependent manner. (A) IBRS-2 cells treated with different concentrations of BFA for 30 min were fixed and
processed for immunofluorescence using a MAb against the cis-Golgi. (B) IBRS-2 cells treated with BFA as in (A) were infected with SVDV (moi of 0.5 pfu/cell) in
presence of the drug. At 8 h pi the viral titer was determined by plaque assay. Error bars represent SD. The data presented correspond to two independent
experiments. Data were analyzed using ANOVA. Asterisk (*) denote statistically significant differences with P < 0.05.
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additional times in the presence of increased concentrations of
BFA (1, 1.5, 2, 2.5, and 3 µg/ml) to produce viral populations B2-
B6. All serial passages were performed with a moi of 0.01 pfu/cell.
The isolation of the nine BFA-resistant clones was performed
by biological cloning in IBRS-2 cells infected with SVDV B6
population in semisolid agar medium containing 3µg/ml of BFA.
For this purpose, viruses from well isolated lysis plaques (24 h
pi) were picked and amplified by infection in liquid medium
containing 3 µg/ml of BFA.
Viral RNA Extraction, CDNA Synthesis, and
DNA Sequencing
Viral RNA was extracted from supernatants of infected cell
cultures by using TRI Reagent (Sigma). cDNA synthesis and
DNA sequencing were performed as described (Vázquez-Calvo
et al., 2016). Nucleotide positions correspond to those reported
for the SVDV SPA/1/′93 isolate (GenBank KU291213).
Data Analysis
Analysis of the variance (ANOVA) using F Fischer–Snedecor
distribution was performed with statistical package SPSS 19.0
(SPSS Inc.). One asterisk (∗) or two asterisk (∗∗) in the figures
denote statistically significant differences with P < 0.05 or P <
0.005, respectively.
RESULTS
Effect of Golgi Complex Disrupting Agents
on SVDV Infection
Wefirst assessed the cytotoxicity of two different Golgi disrupting
agents, BFA and GCA, on IBRS-2 cells. None of the drug
concentrations tested exerted major cytotoxic effect on IBRS-2
cells after 24 h of treatment, being the amount of cellular ATP
higher than 80% of that of control cells in all cases (Figure 1A).
However, immunofluorescence analyses revealed that treatment
of the cells with these drugs caused the dispersion of a cis-Golgi
complex marker through the cytoplasm of the cells (Figure 1B),
which confirmed the expected effect of these Golgi disrupting
agents. Next, the effect of these drugs on the infection of SVDV
was evaluated. FMDV, a picornavirus that is resistant to BFA
(Martín-Acebes et al., 2008), and the rhabdovirus VSV, which
TABLE 1 | SVDV passages in presence of BFA.
Virus populationa BFA (µg/ml) TCEb (h pi) Viral titer (pfu/ml)
Wt 0.0 18 1.4 × 108
B1 0.5 36 5.9 × 10
6
B2 1.0 40 3.8 × 10
6
B3 1.5 43 8.9 × 10
5
B4 2.0 21 4.9 × 10
7
B5 2.5 24 6.0 × 10
7
B6 3.0 24 6.4 × 10
7
aVirus passaged in the presence of increasing concentrations of BFA. A moi of 0.01 was
used for each passage.
bTime pi at which total cytopathic effect was observed (TCE).
is highly sensitive to Golgi disrupting agents (Martín-Acebes
et al., 2008), were included as controls (Figure 1C). As expected
(O’Donnell et al., 2001; Martín-Acebes et al., 2008; Midgley et al.,
2013), no statistically significant reductions in FMDV titers were
found, whereas VSV production was inhibited by the two drugs
tested. These results indicate that, as described for the enterovirus
CVB3 (van der Linden et al., 2010), SVDV is inhibited by BFA
and GCA.
Isolation of BFA-Resistant SVDV Mutants
A valid strategy to gain information on the viral factors involved
in the resistance to Golgi-disrupting agents such as BFA consists
of the selection and characterization of mutants upon virus
passages in the presence of increasing drug concentrations
(Crotty et al., 2004; Viktorova et al., 2015). As shown in Figure 1,
5 µg/ml BFA caused disruption of the Golgi complex and
inhibited SVDV yield by several orders of magnitude. To search
for conditions for selection of BFA resistant mutants, the effect of
lower drug concentrations was determined. Treatment with 0.5
µg/ml BFA was sufficient to disrupt the Golgi complex in IBRS-
2 cells (Figure 2A) producing a statistically significant reduction
(about two orders of magnitude) in the viral titer (Figure 2B).
Then, SVDV was subjected to 6 serial passages in the presence
of increasing concentrations of BFA, starting from 0.5 µg/ml up
to 3 µg/ml in passage 6 (Table 1). During these passages viruses
were harvested when total cytopathic effect was observed (usually
about 24–40 h pi.). These viral populations were termed B1 to
B6. In these experiments, we observed that although infections
were performed using the same moi in each passage, the viral
titer increased with the passage number, which was consistent
with the selection of BFA-resistant viruses. To test whether the
B6 population displayed increased resistance to BFA, IBRS-2 cells
were infected in presence of different concentrations of the drug
and the viral titers determined were compared with those from
cells infected with the initial SVDV population, termed wt. The
FIGURE 3 | SVDV B6 is more resistant to BFA than SVDV wt. IBRS-2
cells treated with different concentrations of BFA for 30 min were infected with
SVDV wt or SVDV B6 (moi of 0.5 pfu/cell) in presence of the drug. At 8 h pi the
viral titer was determined by plaque assay. Error bars represent SD. Data were
analyzed using ANOVA. Two asterisks (**) denote statistically significant
differences with P < 0.005.
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TABLE 2 | Mutations found in the genome of SVDV mutants with increased resistance to BFA.
Genomic
region
Mutations found in viral populationa
B6 br1 br2 br3 br4 br5 br6 br7 br8 br9
VP1 A2269A/G
Q134Q/Rb
A2269G
Q134R
A2269G
Q134R
A2269G
Q134R
A2269G
Q134R
2C G3610A
R49K
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
G3659T
Q65H
3A A4575G A4575G
3C T4807T/C
V8V/Ab
T4807C
V8A
T4807C
V8A
T4807C
V8A
T4807C
V8A
T4807C
V8A
T4807C
V8A
aB6 refers to viral population recovered after 6 passages in the presence of increasing concentrations of BFA (see Material and Methods for details). br1 to br9 refer to independent
biological clones isolated from B6. The complete coding region of B6 population was sequenced. Only genomic regions showing nucleotide replacements are included in the Table. For
clones br1-br9, only the regions where B6 populations exhibited nucleotide substitutions were sequenced. The nucleotide position in the SVDV SPA/1/′93 genome (GenBank KU291213)
and the substitution found are indicated. For non-synonymous substitutions, amino acid replacements are shown in bold.
bNucleotide mixture at this position. See the text for details.
FIGURE 4 | Susceptibility of clones derived from SVDV B6 to BFA.
IBRS-2 cells were infected with SVDV wt or the different drug resistant br1-9
clones at a moi of 0.1 pfu/cell and then incubated for 40 h in the absence or
presence of 2 µg/ml BFA.
virus yield displayed by the wt virus was similar or even higher
to that of B6 population in the absence of the drug (Figure 3).
Conversely, the virus titers found in the viral population B6
grown in the presence of 3 or 5 µg/ml BFA were about two
orders of magnitude higher than those of the wt. These results
confirmed that SVDV population B6 showed increased resistance
to BFA.
The Amino Acid Substitution Q65H in the
SVDV 2C Protein Confers Resistance to
BFA
To identify the genotypic changes responsible for the increased
resistance to BFA in the SVDV population B6, the complete
coding region sequences of the wt and B6 SVDV populations
were determined and compared. The analysis of chromatograms
of B6 population showed a single non-synonymous nucleotide
replacement, G3659T, imposed, leading to amino acid
replacement Q65H in the 2C protein (Table 2). Two additional
positions with nucleotide mixture were also observed in B6
population: A2269A/G in a 42/58 ratio (G leading to substitution
VP1 Q134R) and T4807T/C in a 53/47 ratio (C leading to
replacement 3C V8A). To confirm the imposition of replacement
2C Q65H (G3659T) nine biological clones (termed br1-9)
isolated from cells infected with B6 population and maintained
in a semi-solid medium containing BFA, were amplified by a
single infection in liquid medium in presence of BFA (3 µg/ml).
Nucleotide sequencing of the 2C-3A coding regions (Table 2)
confirmed that replacement 2C Q65H was present in all clones
analyzed (br1-9). Virus br1 and br4 showed an additional
synonymous change (A4575G), and virus br8 exhibited an
additional non-synonymous nucleotide change G3610A, leading
to replacement R49K in 2C protein. Changes A2269G (VP1
Q134R) and T4807C (3C V8A) partially imposed in the parental
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B6 population were found in the RNA of four (br2, br5, br7, and
br9) and two (br3 and br6) of the clones analyzed, respectively.
These results indicate that 2C Q65H, the only replacement found
in the nine clones analyzed, is likely to be responsible of the
increased resistance to BFA displayed by the B6 population. Next,
the growth of br1-9 clones in the presence of BFA was analyzed
(Figure 4). At low moi (0.01 pfu/cell), while the wt virus lysed
the cells in the absence of drug, it did not produce detectable
cytopathic effect in the presence of BFA. On the contrary, viruses
br1-9 produced a similar cytopathic effect in both situations,
which confirms that replacement 2C Q65H confers SVDV
resistance to BFA.
The comparison of 86 complete 2C protein sequences of
different enterovirus retrieved from a BLAST analysis (Mount,
2007) showed that residue Q65 is invariant in all the viruses
compared (Table 3). To test the stability of the nucleotide
substitution G3659T responsible for replacement Q65H, the
SVDV B6 population was serially passaged ten times in the
absence of BFA. The substitution G3659T was conserved in the
average population after these passages, confirming its genetic
stability (Figure 5).
BFA-Resistant SVDV br1 Induces Golgi
Disassembly
SVDV infection of IBRS-2 cells disassembles ER and Golgi
complex. In addition to this, the viral protein 2C is mainly
located perinuclearly whit a punctuated pattern labeling the viral
replication complexes (Martín-Acebes et al., 2008). In order
to study whether the membrane rearrangements produced by
BFA-resistant SVDV were different from those of SVDV wt,
IBRS-2 cells were infected with SVDVwt or br1 and processed for
immunofluorescence analysis (Figure 6). SVDV br1 was selected
for these experiments because this mutant only differs from the
wt on the amino acid replacement 2C Q65H (Table 2). SVDV
br1 infection disassembled the cis-Golgi as occurred with the
wt infection (Figure 6A). Moreover, the perinuclear localization
of 2C and its distribution pattern was indistinguishable from
that of wt SVDV (Figure 6). In addition, 2C colocalized with
the dsRNA fluorescence in both wt and br1 SVDV-infected
cells (Figure 6B). These results indicate that replication of the
BFA-resistant SVDV induces Golgi disassembly and does not
display remarkable differences with the wt virus in the cellular
membranes rearrangements produced and the viral replication
complex localization.
The Amino Acid Substitution Q65H in the
SVDV 2C Protein Also Confers Resistance
to GCA
The production of SVDV was inhibited by BFA as well as by the
Golgi disrupting agent GCA (Figure 1C). To test whether the
SVDVB6 population was also resistant to GCA, IBRS-2 cells were
infected with SVDV wt or B6 in presence of 10 µMGCA and the
viral titer was determined 8 h pi (Figure 7). These experiments
showed an increase in the resistance to GCA of SVDV as its
multiplication was inhibited about 1 order of magnitude less in
the presence of GCA than that of SVDVwt. These results indicate
that replacement 2C Q65H is responsible for the resistance to
agents that inhibit GBF1.
TABLE 3 | Representative multiple sequence alignment of 2C proteins from different enterovirus and the SVDV strain used in this work (SVDV SPA/1/′93).
Virus Amino acid sequence of 2C protein GenBank
accesion
SVDV spa93 NSGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQGDQEQLFSNVQYFAHYCRKYAPLYAAEAKR KU291213
SVDV Itl NSGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQGDQEQLFSNVQYFAHYCRKYAPLYAAEAKR EU151461.1
CVB5 NNGWLKKFTEMTNACKGMEWIAVKIQKFIEWLKVRILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQGDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33411.1
CVB4 NNSWLKKFTEMTNACKGMEWIAVKIQKFIEWLKVRILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33464.1
CVB3 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWIKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYATEAKR CCW33459.1
CVB2 SNGWLKKFTEMTNACKGMEWIAVKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYATEAKR CCW33458.1
CVA9 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVREKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33456.1
EVB83 NNNWLKKFTEMTNACKGMEWIAVKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFTNVQYFAHYCRKYAPLYAAEAKR CCW33489.1
EV13 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKVLPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYATEAKR AAX63470.2
ECHO30 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVREKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR AAS83471.3
ECHO21 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVREKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33484.1
ECHO25 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKIMPEVKEKHEFLNRLKQLPLLESQVATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33486.1
ECHO6 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVREKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CBL42967.1
ECHO33 NNGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQITTIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33488.1
ECHO2 NSGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33466.1
ECHO14 NSGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKVKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33478.1
ECHO18 NSGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKIKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33479.1
ECHO3 NSGWLKKFTEMTNACKGMEWIAIKIQKFIEWLKIKILPEVKEKHEFLNRLKQLPLLESQIATIEQSAPSQSDQEQLFSNVQYFAHYCRKYAPLYAAEAKR CCW33467.1
PV GDSWLKKFTEACNAAKGLEWVSNKISKFIDWLKEKIIPQARDKLEFVTKLRQLEMLENQISTIHQSCPSQEHQEILFNNVRWLSIQSKRFAPLYAVEAKR ACX85868.1
* * * * * * * * * * * * * ** * * * * * * ** * * * * * * * * * * * ** * * * * * * * * * * * * * * * * * * * *
Residues 1–100 are shown in the figure. The residues found replaced in SVDV br1-br9 BFA resistant viruses are highlighted: R49 in red and Q65 in green. Residues invariant in the
alignment are indicated by *.
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FIGURE 5 | Genetic stability of the nucleotide replacement G3659T. SVDV B6 was passaged ten times in absence of BFA. The viral RNA of the passages 5 and
10 was extracted and the nucleotide sequence was determined. Representative chromatograms of the region encoding 2C protein are shown of SVDV wt, SVDV B6,
SVDV B6 passage 5 and SVDV B6 passage 10.
DISCUSSION
The study of the molecular factors usurped by viruses in
their cellular hosts provides valuable information to understand
virus-host interactions. Picornaviruses reorganize the cellular
membranes of the infected cells to generate specialized organelles
for viral RNA replication, but how this process occurs is not
yet fully understood. SVDV infection disassembles the ER and
the Golgi complex and the viral replication takes place at the
surface of cytoplasmic vesicle-like structures likely originated
from these organelles (Martín-Acebes et al., 2008). However, the
differences in the morphology of cytoplasmic rearrangements
induced in infected cells and in the sensitivity to Golgi-disrupting
agents, like BFA or GCA, suggest the existence of diverse cellular
requirements among picornaviruses to form the replication
complex (Moffat et al., 2005; Wessels et al., 2006a; Martín-
Acebes et al., 2008; van der Linden et al., 2010). In fact, there is
evidence of important differences on host factors involved in the
Frontiers in Microbiology | www.frontiersin.org 7 April 2016 | Volume 7 | Article 612
Vázquez-Calvo et al. SVDV Mutants Resistant to BFA
FIGURE 6 | Effect of the infection on Golgi complex and cellular localization of viral protein 2C. (A) IBRS-2 cells infected with SVDV wt or br1 (moi of 0.5
pfu/cell) and processed for double immunofluorescence, at 8 h pi, using MAb to GM130 (cis-Golgi) or a rabbit polyclonal serum to 2C protein. (B) IBRS-cells infected
and processed for immunofluorescence as in (A) using MAb to dsRNA or a rabbit polyclonal serum to 2C protein. The right panels represent the detail inside the box.
Nuclei were stained using Topro-3. Bar: 20 µm.
replication of the picornaviruses, such as COP-I (Gazina et al.,
2002), Arf1 (Midgley et al., 2013; Wang et al., 2014b), ACBD3
(acyl-CoA binding domain containing 3) (Greninger et al., 2012)
or the recruitment of phosphatidylinositol 4-kinase class III β
(PI4KIIIβ) (Sasaki et al., 2012; Dorobantu et al., 2014, 2015).
In the present study, we have documented the sensitivity
of SVDV infection to BFA and GCA, two different drugs that
target the secretory pathway. BFA inhibits GBF1, BIG1 and
BIG2; three members of a family of GEFs that activate several
small Arf GTPases (Belov and Sztul, 2014), while GCA is a
specific inhibitor of GBF1 (Sáenz et al., 2009; Belov and Sztul,
2014). The effect of BFA and GCA on SVDV production was
similar, which could indicate that, as proposed for PV and
CVB3, the sensitivity of SVDV infection to BFA inhibition is
dependent on GBF1, but not on BIG1/2 (Belov et al., 2008;
Lanke et al., 2009; van der Linden et al., 2010). Furthermore,
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the BFA-resistant SVDVs here described also displayed increased
resistance to GCA, supporting that the molecular basis of BFA
resistance is related to GBF1, which is specifically inhibited by
GCA. Overall, our results suggest that the inhibition on SVDV
replication by BFA and GCA relies on its effect on GBF1.
In fact, GBF1 variants unable to activate Arf1 can partially
rescue enterovirus replication from BFA inhibition, which is
also consistent with the view that GBF1 actually plays a role
in enterovirus replication regardless its ability to activate Arf1
(Belov et al., 2010). On the other hand, while PV mutants
resistant to BFA can be selected in Hela cells, the isolation
process was not possible in Vero cells as a consequence of the
lower availability of GBF1 for the formation of the replication
complex in this cell line (Viktorova et al., 2015). Moreover,
studies performed with Aichi virus, another picornavirus not
sensitive to BFA, showed that the replication of this virus is
strongly inhibited by a siRNA-mediated knockdown of GBF1
(Greninger et al., 2012), further supporting a role of GBF1 on
picornavirus replication independently of its ability to activate
Arf1. The results presented here are similar to those reported
for other enterovirus such as PV and CVB3 (Lanke et al., 2009;
Hsu et al., 2010; Viktorova et al., 2015), which suggest that GBF1
could be also localized in the viral replication factories of SVDV.
Nevertheless, there is no direct evidence that GBF1 forms part of
the SVDV replication complex and further work is required to
ascertain this point.
Our analysis revealed that the molecular basis for the
BFA-resistant SVDV here described was related to a single
nucleotide substitution responsible for amino acid replacement
Q65H in non-structural protein 2C. Picornavirus 2C is a
conserved protein (329 amino acids in length for SVDV) with
a hydrophobic N-terminal domain that mediates its binding to
membranes (Echeverri andDasgupta, 1995; Teterina et al., 1997a;
Echeverri et al., 1998). In the case of SVDV, 2C protein colocalizes
with the viral replication sites (Martín-Acebes et al., 2008),
in a parallel manner to that described for other enteroviruses
(Springer et al., 2013), and it is involved in PV membrane
rearrangements (Teterina et al., 1997b). Moreover, 2C plays a
role in PV RNA synthesis (Barton and Flanegan, 1997; Smithee
et al., 2015) and virion packaging (Li and Baltimore, 1990; Liu
et al., 2010; Wang et al., 2014a). Substitution Q65H does not
provoke amajor impact on the cellular distribution of 2C protein,
since both wt and BFA-resistant SVDV exhibited a similar
fluorescent pattern which was associated to viral replication
complexes labeled with dsRNA. Studies performed with PV 2C
protein have revealed that it contains a N-terminal domain
amphipathic helix, two predicted RNA-binding regions, three
motifs involved in NTP binding, and a cysteine-rich putative zinc
finger motif (Springer et al., 2013). Although the 3D structure
of 2C protein has not been solved for any picornavirus, the
secondary structure prediction of SVDV 2C protein using the
Phyre engine (Bennett-Lovsey et al., 2008) located the residue
Q65 immediately after an alpha helix motif, relatively close to
the membrane binding domain (residues 6–54 in the PV 2C
protein) (Echeverri and Dasgupta, 1995; Teterina et al., 1997a;
Echeverri et al., 1998). As commented above, other groups have
previously described PV mutants resistant to BFA carrying point
FIGURE 7 | The amino acid substitution Q65H in 2C confers resistance
to GCA. IBRS-2 cells treated with 10 µM GCA for 30 min were infected with
SVDV wt or SVDV B6 (moi of 0.5 pfu/cell) in presence of the drug. At 8 h pi the
viral titer was determined by plaque assay. Error bars represent SD. Data were
analyzed using ANOVA. Two asterisks (**) denote statistically significant
differences with P < 0.005.
mutations in 2C and 3A proteins (Crotty et al., 2004; Viktorova
et al., 2015). In these cases, the resistance to BFA was mainly
associated with amino acid replacements in the 3A, whereas
the substitution in the 2C seemed to have an auxiliary role.
Indeed, PV 2C and 3A exhibit functional interactions during
viral replication, a direct binding between these proteins has
been reported (Teterina et al., 2006), and mutations in one
protein can be compensated by changes in the other (Teterina
et al., 2006). To our knowledge, there is no evidence of a
direct interaction between enterovirus 2C protein and GBF1,
although it has been demonstrated that the enteroviral protein
3A interacts directly with GBF1 (Wessels et al., 2006a,b, 2007).
Having in mind all these considerations, the molecular basis
of the increase in resistance to BFA observed for our SVDV
mutants could rely on an alteration on their ability to interact
with GBF1, either directly or through its interaction with 3A
protein.
In general, antiviral agents can interfere with viral
components in processes that often lead to development of
drug resistance in virus populations evolving under selective
pressures (Domingo and Gomez, 2007; Colman, 2009). One
of the approaches to evade this limitation is the identification
of antivirals targeted against cellular functions required for
the virus to complete its viral cycle (Khattab, 2009; Ludwig,
2009; Pereira and Jacobson, 2009). Despite BFA targeting a
cellular protein, our results show that the inhibition of SVDV
replication exerted by BFA can be bypassed by the selection
of drug-resistance virus mutants. This is in agreement with
results obtained by other authors using PV (Crotty et al., 2004;
Viktorova et al., 2015), although in our results with SVDV, drug
resistance is mainly associated with changes in 2C protein. These
results also unveil a functional connection between GBF1 protein
and 2C protein in SVDV replication, thus providing further
evidence of the involvement of GBF1 in the replication of this
pathogen.
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